

Special Issue

Advances in Personalized Treatment of Breast Cancer

Message from the Guest Editor

Breast cancer is commonly considered an international health priority, it is the most common tumour in women in the world, and epidemiological data show a progressive increase in its incidence. The evolution of evidence-based guidelines in important disciplines such as surgery, radiotherapy, and medical oncology is leading to a steady improvement in survival rates. The management of breast cancer has progressively evolved towards less aggressive approaches with the adoption of new therapeutic strategies based on integrated and precision oncology. Treatments are personalized for each patient and based on individual peculiarities (age, associated pathologies, presence of genetic mutations) and on the characteristics of the disease (staging, biological, molecular, and genomic profiles). This Special Issue will highlight the recent advances in personalized breast cancer treatment, their potential benefits, and the many open questions that have yet to be properly defined and answered. We invite the following types of manuscripts: original research articles; meta-analyses; systematic reviews; review articles; method articles; perspective articles; and technology reports.

Guest Editor

Dr. Gianluca Franceschini

Breast Unit, Dipartimento Scienze della Salute della Donna e del Bambino e di Sanità Pubblica, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica, Rome, Italy

Deadline for manuscript submissions

closed (10 July 2025)



Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/si/177907

*Journal of Personalized
Medicine*
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jpm@mdpi.com

mdpi.com/journal/

jpm





Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/journal/

jpm



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine is one of the few journals that covers the diverse areas involved in the field, including research at basic, translational, and clinical levels. It focuses on “omics”-level studies that seek to define the basis of interindividual variation in susceptibility for a disease, its prognosis or definition of clinical subsets, and response to therapy (pharmacogenomics). We are also interested in systems biology as it relates to interindividual variation, and research on new methodologies, informatics, and biostatistics, in the aforementioned areas.

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W.F, Toronto, ON M5S 3H2, Canada

Author Benefits

High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 25 days after submission; acceptance to publication is undertaken in 5.8 days (median values for papers published in this journal in the second half of 2025).